Floatz logo

Pembrolizumab

Thyroid Carcinoma

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Thyroid Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
LENVATINIB
University Medical Center Groningen
Phase 4BB
Olaparib
University Medical Center Groningen
Phase 4BB
gw786034
University Medical Center Groningen
Phase 4B
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 39 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →